Abivax SA (Euronext Paris, NASDAQ:ABVX) reports reaching the 600-patient enrollment milestone for its Phase 3 ABTECT trial to evaluate its lead investigational drug candidate, Obefazimod, in patients with moderate-to-severe ulcerative colitis (UC). The study is expected to reach full enrollment in early Q1 2025.
Obefazimod is an orally administered small molecule that was demonstrated to potentially enhance the expression of a single microRNA, miR-124. Phase 2 clinical trials in patients with UC produced positive results, leading to the initiation of the pivotal global Phase 3 clinical trial program. The first patients were enrolled in the U.S. in October 2022.
The company anticipates launching a Phase 2b clinical trial of Obefazimod in Crohn’s disease this year. The exploration of potential combination therapy opportunities in UC is ongoing.
Abivax, based in France and the U.S., is a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
